[Prognosis in stage a prostate cancer]

Area of Science:

• Urology
• Oncology
• Medical Research

Context:

• Prostate cancer diagnosis and staging are critical for treatment and prognosis.
• Stage A prostate cancer represents an early stage of the disease, often detected incidentally.
• Understanding subclassifications (A1 and A2) is important for predicting patient outcomes.

Purpose:

• To investigate the characteristics, treatment, and prognosis of stage A prostate cancer, specifically subclassifying into A1 and A2.
• To analyze the correlation between prostate-specific antigen (PSA) levels, treatment modalities, and outcomes in stage A prostate cancer patients.
• To evaluate the progression and survival rates for stage A1 and A2 prostate cancer.

Summary:

• A study of 80 stage A prostate cancer cases (subclassified into A1 and A2) in Japan revealed differences in prostate-specific antigen (PSA) positivity and endocrine therapy use.
• Stage A1 cases showed 18.5% PSA positivity and 45.5% endocrine therapy, while stage A2 cases had 53.8% PSA positivity and 78.7% endocrine therapy.
• Progression rates were low (3.0% in A1, higher in A2), with 5-year survival rates of 97.0% for A1 and 88.6% for A2, indicating a favorable prognosis for stage A prostate cancer.

Impact:

• This research provides valuable data on the clinical behavior and outcomes of early-stage prostate cancer.
• Findings can aid clinicians in refining treatment strategies and patient counseling for stage A prostate cancer.
• The study highlights the importance of subclassifying stage A prostate cancer for accurate prognostic assessment.